Nanoparticle Albumin-Bound Paclitaxel/Liposomal-Encapsulated Doxorubicin in HER2-Negative Metastatic Breast Cancer Patients
F. Cognetti(Sapienza University of Rome), Simona Gasparro(National Cancer Institute), Grazia Arpino(University of Naples Federico II), Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giovanna Catania(Istituti di Ricovero e Cura a Carattere Scientifico), Francesco Schettini(Target (United States)), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Michelangelo Russillo(National Cancer Institute), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), Paola Malaguti
Cited by 13
Related Papers
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
|Annals of Oncology|2016|398
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240